Versor Investments LP Lowers Stock Position in Repligen Co. (NASDAQ:RGEN)

Versor Investments LP cut its stake in shares of Repligen Co. (NASDAQ:RGEN) by 43.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,367 shares of the biotechnology company’s stock after selling 2,634 shares during the quarter. Versor Investments LP’s holdings in Repligen were worth $485,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. Resources Management Corp CT ADV purchased a new position in shares of Repligen during the 3rd quarter valued at $37,000. Quarry LP boosted its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the period. UMB Bank n.a. increased its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after buying an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC raised its holdings in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 129 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Up 1.7 %

Shares of NASDAQ RGEN opened at $159.26 on Friday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $203.13. The firm’s 50-day moving average price is $156.17 and its 200-day moving average price is $148.67. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of -312.27, a P/E/G ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, equities research analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on RGEN shares. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.